{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:14:54Z","timestamp":1791584094042,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T00:00:00Z","timestamp":1194393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s10741-007-9060-z","type":"journal-article","created":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T21:03:16Z","timestamp":1194382996000},"page":"367-375","source":"Crossref","is-referenced-by-count":84,"title":["Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies"],"prefix":"10.1007","volume":"13","author":[{"given":"John W.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiko","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,7]]},"reference":[{"key":"9060_CR1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/0002-8703(91)90694-D","volume":"121","author":"V Dzau","year":"1991","unstructured":"Dzau V, Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121:1244\u20131263","journal-title":"Am Heart J"},{"key":"9060_CR2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","volume":"23","author":"V Dzau","year":"2005","unstructured":"Dzau V (2005) The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 23:S9\u2013S17","journal-title":"J Hypertens"},{"key":"9060_CR3","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","volume":"114","author":"VJ Dzau","year":"2006","unstructured":"Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114:2850\u20132870","journal-title":"Circulation"},{"key":"9060_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.ph.54.030192.001303","volume":"54","author":"KM Baker","year":"1992","unstructured":"Baker KM, Booz GW, Dostal DE (1992) Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227\u2013241","journal-title":"Annu Rev Physiol"},{"key":"9060_CR5","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2006","unstructured":"Mehta PK, Griendling KK (2006) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82\u2013C97","journal-title":"Am J Physiol Cell Physiol"},{"key":"9060_CR6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","volume":"101","author":"B Schieffer","year":"2000","unstructured":"Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M et\u00a0al (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372\u20131378","journal-title":"Circulation"},{"issue":"Suppl 2","key":"9060_CR7","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/61.suppl_2.S4","volume":"61","author":"KF Adams","year":"2004","unstructured":"Adams KF (2004) Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm 61(Suppl 2):S4\u2013S13","journal-title":"Am J Health Syst Pharm"},{"key":"9060_CR8","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","volume":"89","author":"T Unger","year":"2002","unstructured":"Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A\u201310A","journal-title":"Am J Cardiol"},{"key":"9060_CR9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0895-7061(98)00254-4","volume":"12","author":"M Schena","year":"1999","unstructured":"Schena M, Mulatero P, Schiavone D, Mengozzi G, Tesio L, Chiandussi L, Veglio F (1999) Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. Am J Hypertens 12:388\u2013397","journal-title":"Am J Hypertens"},{"key":"9060_CR10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI118623","volume":"97","author":"S Rajagopalan","year":"1996","unstructured":"Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH\/NADPH oxidase activation. Contribution to alterations of vasomotortone. J Clin Invest 97:1916\u20131923","journal-title":"J Clin Invest"},{"key":"9060_CR11","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/01.CIR.0000015603.84788.47","volume":"105","author":"D Kalra","year":"2002","unstructured":"Kalra D, Sivasubramanian N, Mann DL (2002) Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 105: 2198\u20132205","journal-title":"Circulation"},{"key":"9060_CR12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1172\/JCI117786","volume":"95","author":"EP Feener","year":"1995","unstructured":"Feener EP, Northrup JM, Aiello LP, King GL (1995) Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353\u20131362","journal-title":"J Clin Invest"},{"key":"9060_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pneurobio.2004.03.003","volume":"72","author":"JW Wright","year":"2004","unstructured":"Wright JW, Harding JW (2004) The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol 72:263\u2013293","journal-title":"Prog Neurobiol"},{"key":"9060_CR14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0195-668X(02)00829-1","volume":"24","author":"DJ Lips","year":"2003","unstructured":"Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA (2003) Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24:883\u2013896","journal-title":"Eur Heart J"},{"key":"9060_CR15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.HYP.33.4.1013","volume":"33","author":"D Lombardi","year":"1999","unstructured":"Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ (1999) Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension 33:1013\u20131019","journal-title":"Hypertension"},{"key":"9060_CR16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/hy1201.100589","volume":"38","author":"M Ruiz-Ortega","year":"2001","unstructured":"Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S et\u00a0al (2001) Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38:1382\u20131387","journal-title":"Hypertension"},{"key":"9060_CR17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/01.RES.68.1.141","volume":"68","author":"H Yamada","year":"1995","unstructured":"Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn AO (1995) Localization of angiotensin converting enzyme in rat heart. Circ Res 68:141\u2013149","journal-title":"Circ Res"},{"key":"9060_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.25.2.219","volume":"25","author":"M Falkenhahn","year":"1995","unstructured":"Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S et\u00a0al (1995) Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 25:219\u2013226","journal-title":"Hypertension"},{"key":"9060_CR19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI316","volume":"101","author":"A Leri","year":"1998","unstructured":"Leri A, Claudio PP, Li Q (1998) Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:1326\u20131342","journal-title":"J Clin Invest"},{"key":"9060_CR20","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1161\/01.CIR.92.12.3568","volume":"92","author":"M Ruzicka","year":"1995","unstructured":"Ruzicka M, Skarda V, Leenen FH (1995) Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 92:3568\u20133573","journal-title":"Circulation"},{"key":"9060_CR21","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1172\/JCI116020","volume":"90","author":"H Schunkert","year":"1992","unstructured":"Schunkert H, Ingelfinger JR, Hirsch AT (1992) Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90:1523\u20131529","journal-title":"J Clin Invest"},{"key":"9060_CR22","doi-asserted-by":"crossref","first-page":"11035","DOI":"10.1073\/pnas.93.20.11035","volume":"93","author":"YA Lee","year":"1996","unstructured":"Lee YA, Liang CS, Lee MA, Lindpaintner K (1996) Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in\u00a0vivo: a comprehensive study of all its components in the dog. Proc Natl Acad Sci USA 93:11035\u201311040","journal-title":"Proc Natl Acad Sci USA"},{"key":"9060_CR23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cardiores.2004.06.012","volume":"63","author":"KD Schluter","year":"2004","unstructured":"Schluter KD, Wollert KC (2004) Synchronization and integration of multiple hypertrophic pathways in the heart. Cardiovasc Res 63:367\u2013372","journal-title":"Cardiovasc Res"},{"key":"9060_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10557-005-6900-8","volume":"19","author":"P Pagliaro","year":"2005","unstructured":"Pagliaro P, Penna C (2005) Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs & Therapy 19:77\u201387","journal-title":"Cardiovasc Drugs & Therapy"},{"key":"9060_CR25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/hh0202.104109","volume":"90","author":"WG Thomas","year":"2002","unstructured":"Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD (2002) Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135\u2013142","journal-title":"Circ Res"},{"key":"9060_CR26","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI13627","volume":"108","author":"C Pellieux","year":"2001","unstructured":"Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, Beermann F et\u00a0al (2001) Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 108:1843\u20131851","journal-title":"J Clin Invest"},{"key":"9060_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1124\/jpet.104.065185","volume":"310","author":"Y Xia","year":"2004","unstructured":"Xia Y, Karmazyn M (2004) Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation. J Pharmacol Exp Ther 310:43\u201351","journal-title":"J Pharmacol Exp Ther"},{"key":"9060_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00004872-199109010-00003","volume":"9","author":"H Kato","year":"1991","unstructured":"Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T (1991) Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 9:17\u201322","journal-title":"J Hypertens"},{"key":"9060_CR29","doi-asserted-by":"crossref","first-page":"26592","DOI":"10.1074\/jbc.M502906200","volume":"80","author":"M Mifune","year":"2005","unstructured":"Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ et\u00a0al (2005) Protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 80:26592\u201326599","journal-title":"J Biol Chem"},{"key":"9060_CR30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0166-2236(96)30013-1","volume":"19","author":"RD Fields","year":"1996","unstructured":"Fields RD, Itoh K (1996) Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Trends Neurosci 19:473\u2013480","journal-title":"Trends Neurosci"},{"key":"9060_CR31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0955-0674(97)80115-9","volume":"9","author":"M Schachner","year":"1997","unstructured":"Schachner M (1997) Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 9:627\u2013634","journal-title":"Curr Opin Cell Biol"},{"key":"9060_CR32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/path.1400","volume":"200","author":"I Stamenkovic","year":"2003","unstructured":"Stamenkovic I (2003) Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 200:448\u2013464","journal-title":"J Pathol"},{"key":"9060_CR33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/0929867013373417","volume":"8","author":"A Jeng","year":"2001","unstructured":"Jeng A, Gonnell N, Skiles J (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 8:425\u2013474","journal-title":"Curr Med Chem"},{"key":"9060_CR34","first-page":"628","volume-title":"The principle and practice of medicine","author":"W Osler","year":"1992","unstructured":"Osler W (1992) The principle and practice of medicine. Appleton and Company, New York, pp 628\u2013635"},{"key":"9060_CR35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.pcad.2006.02.001","volume":"48","author":"AH Gradman","year":"2006","unstructured":"Gradman AH, Alfayoumi F (2006) From left ventricular hypertophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 48:326\u2013341","journal-title":"Prog Cardiovasc Diseases"},{"key":"9060_CR36","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/01.CIR.94.9.2285","volume":"94","author":"EJ Eichhorn","year":"1996","unstructured":"Eichhorn EJ, Bristow MR (1996) Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 94:2285\u20132296","journal-title":"Circulation"},{"key":"9060_CR37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-0-387-30381-9_27","volume-title":"Handbook of neurochemistry and molecular neurobiology: neuroactive proteins and peptides","author":"JW Wright","year":"2006","unstructured":"Wright JW, Harding JW (2006) Angiotensins in brain function. In: Lim R (ed) Handbook of neurochemistry and molecular neurobiology: neuroactive proteins and peptides. Springer Science, New York, pp 627\u2013653"},{"key":"9060_CR38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3317\/jraas.2003.008","volume":"4","author":"A Stanton","year":"2003","unstructured":"Stanton A (2003) Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:6\u201310","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"9060_CR39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003495-199000391-00005","volume":"39","author":"CI Johnston","year":"1990","unstructured":"Johnston CI (1990) Biochemistry and pharmacologyof the renin-angiotensin system. Drugs 39:21\u201331","journal-title":"Drugs"},{"key":"9060_CR40","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI118186","volume":"96","author":"ID Zisman","year":"1995","unstructured":"Zisman ID, Abraham WT, Meiixell GE (1995) Angiotensin II formation in the intact human heart. Predominance of the angiotensin converting enzyme pathway. J Clin Invest 96:1490\u20131498","journal-title":"J Clin Invest"},{"key":"9060_CR41","first-page":"63","volume-title":"Heart Failure","author":"IJ Dell\u2019Italia","year":"2004","unstructured":"Dell\u2019Italia IJ, Sabri A (2004) Activation of the renin-angiotensin system in hypertrophy and heart failure. In: Mann DL (ed) Heart Failure. Saunders, Philadelphia PA, pp 63\u201376"},{"key":"9060_CR42","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI119360","volume":"99","author":"YH Liu","year":"1997","unstructured":"Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926\u20131935","journal-title":"J Clin Invest"},{"key":"9060_CR43","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355\u20131364","journal-title":"Circ Res"},{"key":"9060_CR44","first-page":"H1379","volume":"260","author":"HN Sabbah","year":"1991","unstructured":"Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S et\u00a0al (1991) A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 260:H1379\u2013H1384","journal-title":"Am J Physiol"},{"key":"9060_CR45","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et\u00a0al (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100:1056\u20131064","journal-title":"Circulation"},{"key":"9060_CR46","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et\u00a0al (2003) Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831\u20131838","journal-title":"Circulation"},{"key":"9060_CR47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0008-6363(96)00194-0","volume":"33","author":"W Hayashida","year":"1997","unstructured":"Hayashida W, Donckier J, Van Mechelen H, Charlier AA, Pouleur H (1997) Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovasc Res 33:54\u201362","journal-title":"Cardiovasc Res"},{"key":"9060_CR48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/hc0902.104599","volume":"105","author":"K Wachtell","year":"2002","unstructured":"Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlof B et\u00a0al (2002) Change in diastolic left ventricular filing after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 105:1071\u20131076","journal-title":"Circulation"},{"key":"9060_CR49","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000017264.66561.3D","volume":"105","author":"J Diez","year":"2002","unstructured":"Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Ubago J (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512\u20132517","journal-title":"Circulation"},{"key":"9060_CR50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"key":"9060_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-108-1-7","volume":"108","author":"D Levy","year":"1988","unstructured":"Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The framingham heart study. Ann Intern Med 108:7\u201313","journal-title":"Ann Intern Med"},{"key":"9060_CR52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/sj.jhh.1000879","volume":"13","author":"CJ Bulpitt","year":"1999","unstructured":"Bulpitt CJ, Cameron JD, Rajkumar C, Armstrong S, Connor M, Joshi J et\u00a0al (1999) The effect of age on vascular compliance in man: which are the appropriate measures? J Hum Hypertens 13:753\u2013758","journal-title":"J Hum Hypertens"},{"key":"9060_CR53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00002512-199710060-00006","volume":"10","author":"A Svanborg","year":"1997","unstructured":"Svanborg A (1997) Age-related changes in cardiac physiology. Can they be postponed or treated by drugs? Drugs Aging 10:463\u2013472","journal-title":"Drugs Aging"},{"key":"9060_CR54","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.jhh.1000901","volume":"13","author":"NS Beckett","year":"1999","unstructured":"Beckett NS, Connor M, Sadler JD, Fletcher AE, Bulpitt CJ (1999) Orthostatic fall in blood pressure in the very elderly hypertensive: results from the hypertension in the very elderly trial (HYVET)\u2013\u2013pilot. J Hum Hypertens 13:839\u2013840","journal-title":"J Hum Hypertens"},{"key":"9060_CR55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00002512-200320050-00001","volume":"20","author":"TJ Cleophas","year":"2003","unstructured":"Cleophas TJ, van Marum R (2003) Age-related decline in autonomic control of blood pressure: implications for the pharmacological management of hypertension in the elderly. Drugs Aging 20:313\u2013319","journal-title":"Drugs Aging"},{"key":"9060_CR56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2165\/00002512-199405050-00007","volume":"5","author":"J Belmin","year":"1994","unstructured":"Belmin J, Levy BI, Michel JB (1994) Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging 5:391\u2013400","journal-title":"Drugs Aging"},{"key":"9060_CR57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1530\/acta.0.0940552","volume":"94","author":"R Takeda","year":"1980","unstructured":"Takeda R, Morimoto S, Uchida K, Miyamori I, Hashiba T (1980) Effect of age on plasma aldosterone response to exogenous angiotensin II in normotensive subjects. Acta Endocrinol 94:552\u2013558","journal-title":"Acta Endocrinol"},{"key":"9060_CR58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.hco.0000231411.15049.20","volume":"21","author":"BR Dulin","year":"2006","unstructured":"Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21:393\u2013399","journal-title":"Curr Opin Cardiol"},{"key":"9060_CR59","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00005082-200609001-00004","volume":"21","author":"KL Grady","year":"2006","unstructured":"Grady KL (2006) Management of heart failure in older adults. J Cardiovasc Nurs 21:S10\u2013S14","journal-title":"J Cardiovasc Nurs"},{"key":"9060_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"SA Hunt","year":"2005","unstructured":"Hunt SA, Abraham WT, Chin MH (2005) ACC\/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol. 46:1\u201382","journal-title":"J Am Coll Cardiol."},{"key":"9060_CR61","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00002512-200522110-00003","volume":"22","author":"AA Mangoni","year":"2005","unstructured":"Mangoni AA (2005) Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging 22:913\u2013941","journal-title":"Drugs Aging"},{"key":"9060_CR62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543\u2013551","journal-title":"N Engl J Med"},{"key":"9060_CR63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005082-200307000-00006","volume":"18","author":"J Dunbar-Jacob","year":"2003","unstructured":"Dunbar-Jacob J, Bohichick P, Mortimer MK, Sereika SM, Foley SM (2003) Medication adherence in persons with cardiovascular disease. J Cardiovasc Nurs 18:209\u2013218","journal-title":"J Cardiovasc Nurs"},{"key":"9060_CR64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00005082-200307000-00003","volume":"18","author":"EM Stuart-Shor","year":"2003","unstructured":"Stuart-Shor EM, Buselli EF, Carroll DL, Forman DE (2003) Are psychosocial factors associated with the pathogenesis and consequences of cardiovascular disease in the elderly? J Cardiovasc Nurs 18:169\u2013183","journal-title":"J Cardiovasc Nurs"},{"key":"9060_CR65","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/sj.jhh.1001443","volume":"16","author":"P Trenkwalder","year":"2002","unstructured":"Trenkwalder P (2002) Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly. J Hum Hypertens 16:S71\u2013S75","journal-title":"J Hum Hypertens"},{"key":"9060_CR66","first-page":"16","volume":"61","author":"WS Aronow","year":"2006","unstructured":"Aronow WS (2006) Heart failure update: treatment of heart failure with a normal left ventricular ejection fraction in the elderly. Geriatrics 61:16\u201320","journal-title":"Geriatrics"},{"key":"9060_CR67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cger.2006.08.004","volume":"23","author":"WS Aronow","year":"2007","unstructured":"Aronow WS (2007) Treatment of heart failure with abnormal left ventricular systolic function in the elderly. Clin Geriatr Med 23:61\u201381","journal-title":"Clin Geriatr Med"},{"key":"9060_CR68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0031-6997(24)01434-0","volume":"52","author":"S Kim","year":"2000","unstructured":"Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11\u201334","journal-title":"Pharmacol Rev"},{"key":"9060_CR69","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","volume":"275","author":"RE Schmieder","year":"1996","unstructured":"Schmieder RE, Martus P, Klingeil A (1996) Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 275:1507\u20131523","journal-title":"JAMA"},{"key":"9060_CR70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cger.2006.09.001","volume":"23","author":"CM O\u2019Connor","year":"2007","unstructured":"O\u2019Connor CM, Arumugham P (2007) Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. Clin Geriatr Med 23:141\u2013153","journal-title":"Clin Geriatr Med"},{"key":"9060_CR71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00002512-200623020-00004","volume":"23","author":"GN Thomas","year":"2006","unstructured":"Thomas GN, Chan P, Tomlinson B (2006) The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 23:131\u2013155","journal-title":"Drugs Aging"},{"key":"9060_CR72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41\u201346","journal-title":"Am J Med"},{"key":"9060_CR73","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2165\/00003495-200161100-00009","volume":"61","author":"M Sharpe","year":"2001","unstructured":"Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61:1501\u20131529","journal-title":"Drugs"},{"key":"9060_CR74","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00002512-200016030-00006","volume":"16","author":"KL Simpson","year":"2000","unstructured":"Simpson KL, McClellan KJ (2000) Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 16:227\u2013250","journal-title":"Drugs Aging"},{"key":"9060_CR75","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2165\/00003495-200262090-00005","volume":"62","author":"GT Warner","year":"2002","unstructured":"Warner GT, Jarvis B (2002) Olmesartan medoxomil. Drugs 62:1345\u20131353","journal-title":"Drugs"},{"key":"9060_CR76","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.jhh.1001650","volume":"17","author":"GY Lip","year":"2003","unstructured":"Lip GY, Beevers DG (2003) More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 17:747\u2013750","journal-title":"J Hum Hypertens"},{"key":"9060_CR77","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3317\/jraas.2004.024","volume":"5","author":"T Unger","year":"2004","unstructured":"Unger T, Li J (2004) The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 5:S7\u2013S10","journal-title":"J Renin Angiotensin Aldosterone Syst"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-007-9060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-007-9060-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-007-9060-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T03:56:09Z","timestamp":1737518169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-007-9060-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,7]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["9060"],"URL":"https:\/\/doi.org\/10.1007\/s10741-007-9060-z","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,7]]}}}